| Dr Nathan Merlin Tritle, MD | |
|
4700 Point Fosdick Dr Ste 320, Gig Harbor, WA 98335-1706 | |
| (253) 426-6731 | |
| (253) 426-1064 |
| Full Name | Dr Nathan Merlin Tritle |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 4700 Point Fosdick Dr Ste 320, Gig Harbor, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285627281 | NPI | - | NPPES |
| 1285627281 | Other | AZ | HEALTH NET |
| 2204814 | Medicaid | WA | |
| 1285627281 | Other | AZ | AETNA |
| 1285627281 | Other | AZ | CIGNA |
| 1285627281 | Other | AZ | BCBS |
| 1285627281 | Other | AZ | UHC |
| 1285627281 | Other | AZ | AFMC |
| 567224 | Medicaid | AZ | |
| 1285627281 | Other | AZ | HMN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD61222747 (Washington) | Primary |
| 207Y00000X | Otolaryngology | 29088 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Anthony Hospital | Gig harbor, WA | Hospital |
| Harrison Medical Center | Bremerton, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
Omega Healthcare Investors, Inc. today announced that it has agreed to sell shares of its common stock having an aggregate offering price of $33.3 million pursuant to a terms agreement entered into under the equity distribution agreement, dated June 12, 2009, between the Company and BofA Merrill Lynch in connection with the company's previously reported $100 million Equity Shelf Program.
Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.
The Canadian Heart and Stroke Foundation warns that untreated transient ischemic attacks (TIAs) are putting nearly 21,000 Canadians at increased risk of death, stroke or heart attack.
Swedish Cancer Institute and Elekta launch renewed partnership agreement to continue the flow of world-class technology, services to cancer patients in the Pacific Northwest and beyond.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 6 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
Omega Healthcare Investors, Inc. today announced that it has agreed to sell shares of its common stock having an aggregate offering price of $33.3 million pursuant to a terms agreement entered into under the equity distribution agreement, dated June 12, 2009, between the Company and BofA Merrill Lynch in connection with the company's previously reported $100 million Equity Shelf Program.
Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.
The Canadian Heart and Stroke Foundation warns that untreated transient ischemic attacks (TIAs) are putting nearly 21,000 Canadians at increased risk of death, stroke or heart attack.
Swedish Cancer Institute and Elekta launch renewed partnership agreement to continue the flow of world-class technology, services to cancer patients in the Pacific Northwest and beyond.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nathan Merlin Tritle, MD 4700 Point Fosdick Dr Ste 320, Gig Harbor, WA 98335-1706 Ph: (253) 426-6731 | Dr Nathan Merlin Tritle, MD 4700 Point Fosdick Dr Ste 320, Gig Harbor, WA 98335-1706 Ph: (253) 426-6731 |
News Archive
Omega Healthcare Investors, Inc. today announced that it has agreed to sell shares of its common stock having an aggregate offering price of $33.3 million pursuant to a terms agreement entered into under the equity distribution agreement, dated June 12, 2009, between the Company and BofA Merrill Lynch in connection with the company's previously reported $100 million Equity Shelf Program.
Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.
The Canadian Heart and Stroke Foundation warns that untreated transient ischemic attacks (TIAs) are putting nearly 21,000 Canadians at increased risk of death, stroke or heart attack.
Swedish Cancer Institute and Elekta launch renewed partnership agreement to continue the flow of world-class technology, services to cancer patients in the Pacific Northwest and beyond.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 6 days ago
Joseph Shvidler, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4545 Point Fosdick Dr Nw, Gig Harbor, WA 98335 Phone: 253-530-8000 | |
Zephron Gabriel Newmark, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4545 Point Fosdick Dr Nw, Gig Harbor, WA 98335 Phone: 253-530-8293 |